Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ANWNASDAQ:AURACVE:GPHNYSEMKT:IGC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANWAegean Marine Petroleum Network$0.00$0.60▼$5.10$26.64M3.27526,099 shsN/AAURAAura Biosciences$5.84-4.1%$5.63$4.35▼$12.38$306.14M0.43206,590 shs266,431 shsGPHGraphite OneC$0.84+6.3%C$0.87C$0.55▼C$1.07C$85.05M1.0263,255 shs18,700 shsIGCIGC Pharma$0.32-2.8%$0.30$0.25▼$0.55$26.85M1.5336,356 shs214,616 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAURAAura Biosciences-4.11%-0.85%+0.17%-22.03%-22.24%GPHGraphite One+6.33%+7.69%0.00%-14.29%+2.44%IGCIGC Pharma-3.65%-5.65%+6.02%+10.07%+31,699,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANWAegean Marine Petroleum NetworkN/AN/AN/AN/AN/AN/AN/AN/AAURAAura Biosciences2.6129 of 5 stars3.61.00.00.03.93.30.0GPHGraphite OneN/AN/AN/AN/AN/AN/AN/AN/AIGCIGC Pharma1.3199 of 5 stars3.50.00.00.00.61.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANWAegean Marine Petroleum Network 0.00N/AN/AN/AAURAAura Biosciences 3.25Buy$22.00276.71% UpsideGPHGraphite One 0.00N/AN/AN/AIGCIGC Pharma 3.00Buy$3.881,122.40% UpsideCurrent Analyst Ratings BreakdownLatest ANW, GPH, IGC, and AURA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2025AURAAura BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$22.005/23/2025AURAAura BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$19.003/26/2025AURAAura BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$19.003/26/2025AURAAura BiosciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform3/25/2025AURAAura BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$25.003/24/2025AURAAura BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.003/6/2025IGCIGC PharmaAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.50 ➝ $3.50(Data available from 5/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANWAegean Marine Petroleum Network$5.67B0.00N/AN/A$14.96 per share0.00AURAAura BiosciencesN/AN/AN/AN/A$4.58 per shareN/AGPHGraphite OneN/AN/AC$0.01 per share94.17C$0.44 per shareN/AIGCIGC Pharma$1.24M20.44N/AN/A$0.08 per share3.96Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANWAegean Marine Petroleum Network-$29.30M-$0.53N/A0.00N/AN/AN/AN/AN/AAURAAura Biosciences-$76.41M-$1.90N/AN/AN/AN/A-41.57%-36.43%8/14/2025 (Estimated)GPHGraphite One-C$4.90M-C$0.07N/A∞N/AN/A-10.96%-6.61%N/AIGCIGC Pharma-$13M-$0.11N/AN/AN/A-714.16%-122.44%-88.40%N/ALatest ANW, GPH, IGC, and AURA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025AURAAura Biosciences-$0.47-$0.55-$0.08-$0.55N/AN/A3/24/2025Q4 2024AURAAura Biosciences-$0.43-$0.52-$0.09-$0.52N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANWAegean Marine Petroleum Network$0.034.58%N/AN/A N/AAURAAura BiosciencesN/AN/AN/AN/AN/AGPHGraphite OneN/AN/AN/AN/AN/AIGCIGC PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANWAegean Marine Petroleum NetworkN/AN/AN/AAURAAura BiosciencesN/A12.4712.47GPHGraphite One0.021.090.33IGCIGC Pharma0.021.150.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANWAegean Marine Petroleum Network34.60%AURAAura Biosciences96.75%GPHGraphite One0.07%IGCIGC Pharma3.87%Insider OwnershipCompanyInsider OwnershipANWAegean Marine Petroleum NetworkN/AAURAAura Biosciences5.40%GPHGraphite One28.81%IGCIGC Pharma31.48%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANWAegean Marine Petroleum NetworkN/A40.64 millionN/AOptionableAURAAura Biosciences5050.27 million47.25 millionNot OptionableGPHGraphite One20101.25 millionN/ANot OptionableIGCIGC Pharma6179.69 million54.60 millionN/AANW, GPH, IGC, and AURA HeadlinesRecent News About These CompaniesIGC Pharma, Inc.: IGC Pharma's Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer's MarketMay 22, 2025 | finanznachrichten.deOtsuka Holdings Stock Price, Quotes and Forecasts | OTC:OTSKY | BenzingaMay 22, 2025 | benzinga.comIGC Pharma's Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer's MarketMay 22, 2025 | accessnewswire.comIGC Pharma, Inc.: IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC-AD1, at the 2025 Genetic Toxicology Association MeetingMay 12, 2025 | finanznachrichten.deIGC Pharma Presents Genetic Toxicology Safety Data on API in IGC-AD1, at the 2025 Genetic Toxicology Association MeetingMay 12, 2025 | accessnewswire.comIGC Pharma announces strategic investment from advisorsApril 25, 2025 | markets.businessinsider.comIGC Pharma Welcomes Strategic Investment from AdvisorsApril 24, 2025 | accessnewswire.comIGC Pharma Welcomes Industry Leaders to Advisory Board, Supporting Alzheimer's Innovation and AI-Driven ProgramsApril 21, 2025 | accessnewswire.comIGC Pharma expands CALMA trial with addition of Butler Hospital ProgramApril 9, 2025 | markets.businessinsider.comIGC Pharma, Inc.: IGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital's Memory and Aging ProgramApril 8, 2025 | finanznachrichten.deIGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital's Memory and Aging ProgramApril 8, 2025 | accessnewswire.comIGC Pharma announces CALMA Phase 2 trial expansion with Miami Jewish HealthApril 2, 2025 | markets.businessinsider.comIGC Pharma expands CALMA clinical trialApril 2, 2025 | markets.businessinsider.comIGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish HealthApril 1, 2025 | accessnewswire.comIGC Pharma announces additional interim results from IGC-AD1 trialMarch 28, 2025 | markets.businessinsider.comIGC Pharma announces interim data from Phase 2 trial of IGC-AD1March 28, 2025 | markets.businessinsider.comIGC Pharma, Inc.: IGC Pharma's Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep DisturbancesMarch 27, 2025 | finanznachrichten.deIGC Pharma posts promising interim data for Alzheimer’s therapyMarch 27, 2025 | finance.yahoo.comIGC Pharma's Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep DisturbancesMarch 26, 2025 | accessnewswire.comIGC Pharma announces CALMA Phase 2 trial expansionMarch 21, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsNavitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookBy Leo Miller | May 27, 2025View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookQualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongSuper Micro Computer Stock Clears New Path Higher on Saudi OrdersBy Gabriel Osorio-Mazilli | May 22, 2025View Super Micro Computer Stock Clears New Path Higher on Saudi OrdersPalo Alto Networks: Buy The Dip, Long-Term Tailwinds AheadBy Thomas Hughes | May 21, 2025View Palo Alto Networks: Buy The Dip, Long-Term Tailwinds AheadANW, GPH, IGC, and AURA Company DescriptionsAegean Marine Petroleum Network NYSE:ANWAegean Marine Petroleum Network Inc., together with its subsidiaries, operates as a marine fuel logistics company that markets and supplies refined marine fuel and lubricants to vessels in port, at sea, and on rivers worldwide. The company offers fueling services to ocean-going and a range of coastal vessels, including oil tankers, container ships, drybulk carriers, cruise ships, reefers, LNG/LPG carriers, car carriers, and ferries, as well as to marine fuel traders, brokers, and other end-users of marine fuel and lubricants. It also markets and distributes marine lubricants under the Alfa Marine Lubricants brand; and provides a range of shipping services, such as technical support and maintenance, insurance arrangement and handling, financial administration, and accounting services. As of December 31, 2016, the company owned and operated a fleet of 46 bunkering vessels, including 45 double hulls and 1 single hull special purpose vehicle; 15 double hull bunkering vessels with an aggregate carrying capacity of approximately 292,400 deadweight ton (dwt); operated 10 land-based storage facilities with an aggregate storage capacity of approximately 1,075,000 cubic meters; and operated 2 vessels as floating storage facility with a cargo carrying capacity of approximately 86,800 dwt. Aegean Marine Petroleum Network Inc. was founded in 1995 and is headquartered in Athens, Greece.Aura Biosciences NASDAQ:AURA$5.84 -0.25 (-4.11%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$6.20 +0.36 (+6.23%) As of 05/30/2025 06:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.Graphite One CVE:GPHC$0.84 +0.05 (+6.33%) As of 05/30/2025 03:17 PM EasternGraphite One Inc. operates as mineral exploration company in the United States. The company holds interest in the Graphite Creek property that consists of 135 mining claims located on the Seward Peninsula, Alaska. The company was formerly known as Graphite One Resources Inc. and changed its name to Graphite One Inc. in February 2019. Graphite One Inc. was incorporated in 2006 and is headquartered in Vancouver, Canada.IGC Pharma NYSEMKT:IGC$0.32 -0.01 (-2.79%) Closing price 05/30/2025 03:59 PM EasternExtended Trading$0.32 +0.00 (+0.95%) As of 05/30/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Archer Aviation Stock Steadies After Short-Seller Report e.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
